Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given an average recommendation of “Buy” by the eight analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $13.71.

Several research firms have commented on HUMA. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Wednesday, March 12th. Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a report on Wednesday, March 26th.

Humacyte Price Performance

Humacyte stock opened at $1.35 on Friday. Humacyte has a 1-year low of $1.30 and a 1-year high of $9.97. The firm has a 50 day simple moving average of $3.31 and a 200-day simple moving average of $4.37. The stock has a market cap of $169.91 million, a price-to-earnings ratio of -1.01 and a beta of 1.36.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.07. The firm had revenue of $7.23 million for the quarter, compared to analyst estimates of $0.64 million. Equities analysts expect that Humacyte will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humacyte

Institutional investors have recently made changes to their positions in the stock. Woodline Partners LP grew its position in shares of Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock valued at $14,386,000 after purchasing an additional 2,000,268 shares during the period. State Street Corp boosted its position in shares of Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after buying an additional 1,895,529 shares during the period. CenterBook Partners LP acquired a new position in shares of Humacyte during the fourth quarter worth $6,463,000. Brevan Howard Capital Management LP grew its stake in shares of Humacyte by 2,795.1% during the fourth quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company’s stock valued at $4,426,000 after acquiring an additional 846,070 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Humacyte by 10.8% during the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after buying an additional 543,995 shares during the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.